HOPA
Hematology/Oncology Pharmacy Association

Approved/Effective Date:
Approved by:
Annual Review by:
Date Reviewed:

HAZARDOUS DRUG ASSESSMENT

TO BE COMPLETED FOR ANY NEW MEDICATION TO ASSESS IF DRUG SHOULD BE HANDLED AS HAZARDOUS AS DEFINED IN USP GENERAL CHAPTER <800>. IF "YES" IS THE ANSWER TO A QUESTION, CHECK THE BOX. IF "NO" IS THE ANSWER TO A QUESTION, LEAVE THE BOX UNCHECKED.

Drug Name	
Route	

STEP 1:

- ☐ Is the drug on the NIOSH list of hazardous medications?

If Yes, follow the NIOSH designation of hazardous drugs or evaluate if an Assessment of Risk should be completed (proceed to STEP 5). If No, proceed to STEP 2.

STEP 2 (ASSESS IF A DRUG IS ANTINEOPLASTIC):

- ☐ Is the AHFS classification of this drug an antineoplastic (10:00)?
- ☐ Does the drug manufacturer require hazardous drug handling?
- ☐ If not listed in AHFS, or an investigational product, is the drug similar in mechanism of action and toxicity profile to other antineoplastic hazardous drugs?

If Yes to any questions above, the drug is considered an Antineoplastic Hazardous Drug (Group 1). Proceed to STEP 5 to evaluate whether an Assessment of Risk should be completed. If No to either question above, proceed to STEP 3 to continue assessment.

STEP 3 (EVALUATE WHETHER DRUG IS NON-ANTINEOPLASTIC AND HAZARDOUS):

- ☐ Does the drug manufacturer require safe handling guidance?
- ☐ Does the drug exhibit carcinogenicity (e.g. tumors) in humans or animals at near or below prescribed doses?
- ☐ Does the drug cause genotoxicity (e.g. consider drug mechanism of action and if it causes damage to DNA)?
- ☐ Does the drug cause organ toxicities related to its adverse events?

If the answer to one or more of the above questions in STEP 4 is Yes, the drug should be considered a Non-Antineoplastic Hazardous Drug (Group 2). Proceed to STEP 5 to evaluate if an Assessment of Risk should be completed.

STEP 4 (DETERMINE WHETHER DRUG CAUSES REPRODUCTIVE RISK):

- ☐ Does the drug cause only reproductive or developmental toxicity (e.g. fetal harm or require contraception)?

If Yes, the drug is considered a Non-Antineoplastic Hazardous Drug (Group 3). An Assessment of Risk may be conducted (proceed to STEP 5). If none of the above boxes are checked, this drug is considered NOT Hazardous. Stop assessment at STEP 4.

STEP 5 (DETERMINE IF AN ASSESSMENT OF RISK SHOULD BE COMPLETED):

- ☐ Is the sterile dosage form manufactured by an approved vendor in its final form (e.g. pre-packaged/pre-made)?
- ☐ Does the dosage form of the conventionally manufactured antineoplastic product require repackaging or counting only?
- ☐ Does the dosage form of conventionally manufactured non-antineoplastic or reproductive hazardous product require repackaging or counting only?

If Yes to an above question, an Assessment of Risk may be conducted. See the Assessment of Risk Form.
If none of the above boxes are checked, follow institutional procedures for Hazardous or Reproductive Risk drugs.